Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.

ABSTRACT:

Background/aims

Transjugular intrahepatic portosystemic shunts (TIPS) in patients with hepatocellular carcinoma (HCC) may improve access to curative therapies, treat portal hypertension (PH)-related complications without worsening liver function, and increase overall survival. Data on the efficacy and safety of TIPS to treat PH complications in HCC patients, as well as the HCC treatment response, were evaluated.

Methods

Studies reporting efficacy in controlling bleeding/ascites or response to HCC therapy, safety, and survival in patients with HCC and TIPS were searched systematically on PubMed and Embase. An extraction of articles using predefined data fields and quality indicators was used.

Results

We selected 19 studies and found 937 patients treated for ascites/ble

SUBMITTER: Norero B 

PROVIDER: S-EPMC10576600 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature